Journal
REVIEWS IN THE NEUROSCIENCES
Volume 30, Issue 3, Pages 221-232Publisher
WALTER DE GRUYTER GMBH
DOI: 10.1515/revneuro-2018-0017
Keywords
animal models; cognitive impairment; cortical lesions; therapeutic agents
Categories
Funding
- CONICET [11220080100106]
- FONCyT [PICT-2012-0656]
- Baron Foundation
- University Institute, Italian Hospital, Buenos Aires, Argentina
Ask authors/readers for more resources
Multiple sclerosis (MS) is an inflammatory and neurodegencrative disease that involves an intricate interaction between the central nervous system and the immune system. Nevertheless, its etiology is still unknown. MS exhibits different clinical courses: recurrent episodes with remission periods ('relapsing-remitting') that can evolve to a 'secondary progressive' form or persistent progression from the onset of the disease ('primary progressive'). The discovery of an effective treatment and cure has been hampered due to the pathological and clinical heterogeneity of the disease. Historically, MS has been considered as a disease exclusively of white matter. However, patients with progressive forms of MS present with cortical lesions associated with meningeal inflammation along with physical and cognitive disabilities. The pathogenesis of the cortical lesions has not yet been fully described. Animal models that represent both the cortical and meningeal pathologies will be critical in addressing MS pathogenesis as well as the design of specific treatments. In this review, we will address the state-of-the-art diagnostic and therapeutic alternatives and the development of strategies to discover new therapeutic approaches, especially for the progressive forms.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available